NATL HEALTH INVESTORS INC (NHI) 49.36 +1.11 (+2.3%)
49.36 +1.11 (+2.3%)
US63633D1046 - REIT - After market: 49.36 0 (0%)
Fundamental Rating
Taking everything into account, NHI scores 4 out of 10 in our fundamental rating. NHI was compared to 210 industry peers in the Equity Real Estate Investment Trusts (REITs) industry. NHI scores bad on very profitability, while its financial health is fine. Not spectacular, but in line with the averages. NHI is quite expensive at the moment. It does show a decent growth rate.
Profitability
Profitability Rating
NHI has a Profit Margin of 23.87%. This is comparable to the industry average of 27.83%.
NHI has a Piotroski-F score of 5.00. This indicates an average health and profitability for NHI.
NHI's Return On Assets of 2.65% is worse than the rest of the industry. The industry average Return On Assets is 3.34%.
NHI's Return On Equity of 5.23% is worse than the rest of the industry. The industry average Return On Equity is 8.17%.
VS Industry
ROA (2.65%) VS Industry: 39% outperformed.
0.03
26.09
ROE (5.23%) VS Industry: 34% outperformed.
0.08
135.39
Profit Margin (23.87%) VS Industry: 42% outperformed.
0.08
881.04
Valuation
Valuation Rating
NHI's low PEG Ratio, which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
With a Forward Price/Earnings Ratio of 17.27, NHI is valued rather expensively.
With a price book ratio of 1.69, NHI is valued correctly.
When comparing the Enterprise Value to EBITDA ratio of NHI to the average industry ratio of 15.65, NHI is valued in line with its industry peers.
The Price/Earnings Ratio is 33.35, which means the current valuation is very expensive for NHI.
NHI's Price/Earning Ratio is slightly more expensive than the industry average, which is at 21.78.
Compared to an average industry price book ratio of 1.09, NHI is valued more expensive than its industry peers.
VS Industry
Price/Earnings (33.35) VS Industry: 30% outperformed.
510.11
0.67
Price/Book (1.69) VS Industry: 33% outperformed.
46.45
0.08
Enterprise Value/ EBITDA (15.05) VS Industry: 54% outperformed.
128.53
2.05
Growth
Growth Rating
NHI is expected to show a strong growth in Earnings Per Share. In the coming 5 years, the EPS will grow by 43.67% yearly.
The EPS growth is accelerating: in the next 5 years the growth will be better than in the last years.
NHI is expected to show quite a strong growth in Revenue. In the coming 5 years, the Revenue will grow by 10.71% yearly.
When comparing the Revenue growth rate of the last 5 years to the growth rate of the upcoming 5 years, we see that the growth is accelerating.
Looking at the last year, NHI shows a decrease in Revenue. The Revenue has decreased by -6.87% in the last year.
NHI shows a decrease in Revenue. Measured over the last 5 years, the Revenue has been decreasing by -0.04% yearly.
NHI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -39.34%.
NHI shows a very negative growth in Earnings Per Share. Measured over the last 5 years, the EPS has been decreasing by -17.49% yearly.
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | -17.49% | -26.65% | -39.34% | 93.09% | 43.67% | N/A | N/A |
| Revenue | -0.04% | -4.37% | -6.87% | 13.78% | 10.71% | N/A | N/A |
Health
Health Rating
NHI is better placed than average in its industry to meet its short term obligations. Its Current Ratio is much better than the industry average of 0.74.
The Quick Ratio of NHI is much better than the industry average of 0.66.
The Altman-Z score of NHI is much better than the industry average of 0.73.
NHI has a Current Ratio of 1.54. This is a normal value and indicates that NHI is financially healthy and should not expect problems in meeting its short term obligations.
NHI has a Quick Ratio of 1.54. This is a normal value and indicates that NHI is financially healthy and should not expect problems in meeting its short term obligations.
The Debt to Equity ratio of NHI is in line with the industry averages.
NHI has a Piotroski-F score of 5.00. This indicates an average health and profitability for NHI.
NHI has an Altman-Z score of 1.15. This is a bad value and indicates that NHI is not financially healthy and even has some risk of bankruptcy.
VS Industry
Debt/Equity (0.9) VS Industry: 57% outperformed.
21.53
0.00
Quick Ratio (1.54) VS Industry: 77% outperformed.
0.00
90.22
Current Ratio (1.54) VS Industry: 75% outperformed.
0.00
90.22
Altman-Z (1.15) VS Industry: 67% outperformed.
-0.94
37.03
Dividend
Dividend Rating
With a Yearly Dividend Yield of 6.41%, NHI is a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 4.94, NHI pays a bit more dividend than its industry peers.
NHI's Dividend Yield is rather good when compared to the S&P500 average which is at 2.55.
NHI's earnings are growing more than its dividend. This makes the dividend growth sustainable.
NHI has paid a dividend for at least 10 years, which is a reliable track record.
243.62% of the earnings are spent on dividend by NHI. This is not a sustainable payout ratio.
VS Industry
Dividend Yield (6.41%) VS Industry: 71% outperformed.
0.27
13.72
NATL HEALTH INVESTORS INC49.36
NYSE:NHI (3/24/2023, 7:00:00 PM)+1.11 (+2.3%)
Chartmill FA Rating
GICS SectorReal Estate
GICS IndustryGroupReal Estate
GICS IndustryEquity Real Estate Investment Trusts (REITs)
Earnings (Last)02-21 2023-02-21/amc
Earnings (Next)05-08 2023-05-08/amc
Inst Owners62.54%
Inst Owner Change-2.85%
Ins Owners0.58%
Ins Owner Change0%
Market Cap2.14B
Analysts70
Price Target59.98 (21.52%)
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 6.41% |
Dividend Growth(5Y)0.46%
DP243.62%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-Date03-30 2023-03-30 (0.9)
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-47.47%
Min EPS beat(2)-95.23%
Max EPS beat(2)0.3%
EPS beat(4)1
Avg EPS beat(4)-50.39%
Min EPS beat(4)-95.23%
Max EPS beat(4)0.3%
Revenue beat(2)1
Avg Revenue beat(2)-3.95%
Min Revenue beat(2)-9.03%
Max Revenue beat(2)1.13%
Revenue beat(4)1
Avg Revenue beat(4)-7.92%
Min Revenue beat(4)-20.44%
Max Revenue beat(4)1.13%
PT rev (1m)-3.34%
PT rev (3m)-4.39%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-4.23%
EPS NY rev (3m)-4.23%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.93%
Revenue NY rev (3m)-0.93%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 33.35 | ||
| Fwd PE | 17.27 | ||
| P/S | 7.7 | ||
| P/FCF | 11.97 | ||
| P/OCF | 11.56 | ||
| P/B | 1.69 | ||
| P/tB | 1.69 | ||
| EV/EBITDA | 15.05 |
EPS(TTM)1.48
EY3%
EPS(NY)2.86
Fwd EY5.79%
FCF(TTM)4.12
FCFY8.36%
OCF(TTM)4.27
OCFY8.65%
SpS6.41
BVpS29.28
TBVpS29.28
PEG (NY)0.36
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.65% | ||
| ROE | 5.23% | ||
| ROIC | 4.63% | ||
| ROICexc | 4.67% | ||
| ROICexgc | 4.69% | ||
| OM | 51.46% | ||
| PM | 23.87% | ||
| GM | 86.35% |
ROICexgc(3y)5.36%
ROICexcg growth 3Y-7.49%
ROICexcg growth 5Y-5.92%
ROICexc(3y)5.33%
ROICexc growth 3Y-7.44%
ROICexc growth 5Y-5.94%
OM growth 3Y-9.38%
OM growth 5Y-6.23%
PM growth 3Y-22.08%
PM growth 5Y-16.04%
GM growth 3Y-4.19%
GM growth 5YN/A
F-Score5
Asset Turnover0.11
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.9 | ||
| Debt/FCF | 6.41 | ||
| Debt/EBITDA | 5.36 | ||
| Cap/Depr | 8.98% | ||
| Profit Quality | 269.53% | ||
| Current Ratio | 1.54 | ||
| Quick Ratio | 1.54 | ||
| Altman-Z | 1.15 |
F-Score5
WACC6.71%
ROIC/WACC0.7
Cap/Depr(3y)63.45%
Cap/Depr(5y)132.13%
Profit Quality(3y)162.05%
Profit Quality(5y)109.81%
Growth
EPS 1Y-39.34%
EPS 3Y-26.65%
EPS 5Y-17.49%
EPS growth Q2Q-71.43%
EPS Next Y93.09%
EPS Next 2Y43.67%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue growth 1Y-6.87%
Revenue growth 3Y-4.37%
Revenue growth 5Y-0.04%
Revenue growth Q2Q1.44%
Revenue Next Year13.78%
Revenue Next 2Y10.71%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-23.09%
EBIT growth 3Y-13.34%
EBIT growth 5Y-6.26%
EBIT Next Year92.1%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y9.1%
FCF growth 3Y101.73%
FCF growth 5Y34.34%
OCF growth 1Y-12.1%
OCF growth 3Y-8.38%
OCF growth 5Y-1.32%
Fundamental Stock Screener Links
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA